Efficacy and safety of full-length pegylated recombinant factor VIII with extended half-life in previously treated patients with hemophilia A: comparison of data between the general and Japanese study populations

[1]  P. Turecek,et al.  Safety of PEGylated recombinant human full‐length coagulation factor VIII (BAX 855) in the overall context of PEG and PEG conjugates , 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

[2]  B. Konkle,et al.  Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. , 2015, Blood.

[3]  L. Valentino,et al.  The biological efficacy profile of BAX 855, a PEGylated recombinant factor VIII molecule , 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

[4]  M. Ozelo,et al.  Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[5]  J. Mahlangu,et al.  Guidelines for the management of hemophilia , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[6]  H. Ehrlich,et al.  BAX 855, a PEGylated rFVIII product with prolonged half-life , 2011, Hämostaseologie.

[7]  S. Jönsson,et al.  Pharmacokinetics and dose requirements of factor VIII over the age range 3–74 years , 2009, European Journal of Clinical Pharmacology.

[8]  J. Stockman.  Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia , 2009 .

[9]  A. Shapiro,et al.  Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin‐free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A 1 , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

[10]  J. Lusher,et al.  The safety and efficacy of B‐domain deleted recombinant factor VIII concentrates in patients with severe haemophilia A: an update , 2005, Haemophilia : the official journal of the World Federation of Hemophilia.

[11]  S. Björkman.  Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[12]  E. Berntorp,et al.  Pharmacokinetics of Coagulation Factors , 2001, Clinical pharmacokinetics.

[13]  H. Brackmann,et al.  Sucrose Formulated Recombinant Human Antihemophilic Factor VIII Is Safe and Efficacious for Treatment of Hemophilia A in Home Therapy , 2000, Thrombosis and Haemostasis.

[14]  H. Brackmann,et al.  Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy--International Kogenate-FS Study Group. , 2000, Thrombosis and haemostasis.

[15]  E. Gomperts,et al.  A Multicenter Study of Recombinant Factor VIII (RecombinateTM) in Previously Treated Patients with Hemophilia A , 1997, Thrombosis and Haemostasis.

[16]  E. Gomperts,et al.  A multicenter study of recombinant factor VIII (Recombinate(TM)) in previously treated patients with hemophilia A , 1997 .

[17]  P. Mannucci,et al.  Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group. , 1990, The New England journal of medicine.